Oxidative stress reproduces placental abnormalities of preeclampsia.
OBJECTIVE
The activities of placental superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px), but not catalase, are lower than normal in preeclampsia, which could contribute to the uncontrolled placental production of lipid peroxides and thromboxane (TX). Oxidative stress, hyperlipidemia and increased iron levels in the maternal compartment in preeclampsia could be responsible for these placental changes by causing oxidative stress in the placenta.


METHODS
We tested this possibility in vitro by exposing a trophoblast-like cell line, ED27, to a combination of linoleic acid (LA, 90 microM) and an oxidizing solution composed of hypoxanthine, xanthine oxidase and ferrous sulfate (OxLA) for 6 days. For these studies, the cells were treated with dexamethasone (10-8 M) for the first 72 hr. This was done to differentiate the cells into a phenotype more like syncytiotrophoblast cells as evidenced by production of beta-human chorionic gonadotropin (beta-hCG).


RESULTS
After 6 days of exposure to OxLA, the activities of SOD and GSH-Px were significantly decreased as compared to exposure to LA alone. In contrast, catalase activity was increased by OxLA. The OxLA-induced decreases in SOD and GSH-Px activities were attenuated by deferoxamine, an iron chelator, suggesting a role for Fe2+ in the decreased activities. Compared to LA, OxLA significantly increased TX secretion and lipid peroxidation in cells and media at 2, 4 and 6 days. Deferoxamine inhibited the OxLA-induced increase in lipid peroxidation, but not the increase in TX. Isolation of trophoblast cells and villous core tissue from term placentas verified that antioxidant enzyme activity was localized primarily to the trophoblast cell compartment lending validity to the in vitro findings.


CONCLUSIONS
These data mimic the changes in placental SOD, GSH-Px, catalase, TX and lipid peroxidation that occur in preeclampsia suggesting that maternal hyperlipidemia and increased iron levels may be responsible for placental oxidative stress and abnormalities in antioxidants and thromboxane.
Vaughan
J E
JE
Department of Obstetrics, Virginia Commonwealth University, Richmond, VA 23298-0034, USA.
Walsh
S W
SW
D000328:Adult; D000704:Analysis of Variance; D002374:Catalase / Q000378:metabolism*; D002460:Cell Line; D006063:Chorionic Gonadotropin / Q000378:metabolism; D003676:Deferoxamine / Q000494:pharmacology; D005260:Female; D005296:Ferrous Compounds / Q000494:pharmacology; D005979:Glutathione Peroxidase / Q000378:metabolism*; D006801:Humans; D007502:Iron Chelating Agents / Q000494:pharmacology; D019787:Linoleic Acid / Q000494:pharmacology; D015227:Lipid Peroxidation; D018384:Oxidative Stress; D011225:Pre-Eclampsia / Q000201:enzymology*; D011247:Pregnancy; D013482:Superoxide Dismutase / Q000378:metabolism*; D013929:Thromboxane B2 / Q000378:metabolism; D014327:Trophoblasts / Q000201:enzymology*; D014969:Xanthine Oxidase / Q000494:pharmacology
D006063:Chorionic Gonadotropin; D005296:Ferrous Compounds; D007502:Iron Chelating Agents; C020748:ferrous sulfate; D013929:Thromboxane B2; D019787:Linoleic Acid; D002374:Catalase; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase; D014969:Xanthine Oxidase; D003676:Deferoxamine